Cofactor Genomics, Inc. Announces CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for OncoPrism, its Medicare Approved Immunotherapy Test
Cofactor Genomics, Inc., a commercial-stage company bridging the precision medicine gap by decoding RNA, announced that experienced industry leader Chris Parker has been named CEO and Board [...]
Cofactor Genomics expands clinical use of OncoPrism, as their AI enabled RNA test achieves national clinical validation after predicting immunotherapy response in Lung Cancer Patients
Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today the validation and launch of OncoPrism®-NSCLC, an RNA-based diagnostic to [...]
Cofactor Genomics Publishes Clinical Validation of OncoPrism-HNSCC, a Test Leveraging Novel RNA Modeling Technology to Predict Response to Immunotherapy
Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced the publication of their PREDAPT clinical trial (NCT04510129) results in head and [...]
Precision Medicine Global Thought Leader, Dr. Howard McLeod, Joins Cofactor Genomics’ Advisory Board as Cofactor Brings OncoPrism test to Partnered Hospitals
Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today that Dr. Howard McLeod, Pharm.D., FASCO, FCCP, has been appointed to [...]
Cofactor Genomics receives Medicare coverage for OncoPrism®, a machine learning-based RNA oncology test predicting immunotherapy response
Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today that Medicare contractor Palmetto GBA has granted national coverage for [...]
Cofactor Genomics’ Immunotherapy Predictive Diagnostic, OncoPrism, Completes Validation and Moves Into Clinical Use in Head and Neck Cancer Patients
Twenty-five institutions collaborate with Cofactor to validate OncoPrism for use in head and neck cancer patients.
Multidimensional biomarker predicts disease control
In response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma
Cofactor Genomics Opens Enrollment for Non-small Cell Lung Cancer Study of OncoPrism Predictive Diagnostic Assay
SAN FRANCISCO–(BUSINESS WIRE)–Cofactor Genomics, the diagnostics company bridging the precision medicine gap, today announced commencement of a study of its OncoPrism™ assay in [...]
Predictive diagnostics: closing the precision medicine gap
Jarret Glasscock, PhD, CEO of Cofactor Genomics explains how diagnostics are emerging as the key to ensuring the right patients get matched to the right therapy, at the right time. Precision [...]
